M. Bergaglio

496 total citations
18 papers, 396 citations indexed

About

M. Bergaglio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, M. Bergaglio has authored 18 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in M. Bergaglio's work include Cancer Treatment and Pharmacology (8 papers), Neutropenia and Cancer Infections (3 papers) and Breast Cancer Treatment Studies (3 papers). M. Bergaglio is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Neutropenia and Cancer Infections (3 papers) and Breast Cancer Treatment Studies (3 papers). M. Bergaglio collaborates with scholars based in Italy, United Kingdom and Malaysia. M. Bergaglio's co-authors include Lucia Del Mastro, M. Venturini, R. Rosso, Massimo Costantini, Ornella Garrone, Gianfilippo Bertelli, P. Pronzato, Catia Angiolini, Manlio Mencoboni and Sergio Venturini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

M. Bergaglio

17 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Bergaglio Italy 12 223 91 82 77 72 18 396
Mustafa Yaylacı Türkiye 10 187 0.8× 98 1.1× 49 0.6× 30 0.4× 47 0.7× 28 413
M Izuo Japan 12 175 0.8× 66 0.7× 55 0.7× 26 0.3× 103 1.4× 82 425
Izabella Czajka-Oraniec Poland 8 130 0.6× 104 1.1× 54 0.7× 30 0.4× 15 0.2× 17 352
N. Panza Italy 14 250 1.1× 167 1.8× 204 2.5× 35 0.5× 20 0.3× 45 563
Başak Oyan Türkiye 12 155 0.7× 36 0.4× 92 1.1× 25 0.3× 32 0.4× 39 348
Orren Beaty United States 8 133 0.6× 14 0.2× 148 1.8× 41 0.5× 65 0.9× 11 373
Anne Pike United States 6 31 0.1× 115 1.3× 73 0.9× 26 0.3× 45 0.6× 8 395
Qing Huang United States 13 59 0.3× 99 1.1× 98 1.2× 29 0.4× 100 1.4× 47 480
Maddalena Grosso Italy 11 76 0.3× 33 0.4× 105 1.3× 12 0.2× 38 0.5× 31 315
Virendra Patil India 11 92 0.4× 183 2.0× 46 0.6× 64 0.8× 52 0.7× 60 395

Countries citing papers authored by M. Bergaglio

Since Specialization
Citations

This map shows the geographic impact of M. Bergaglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Bergaglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Bergaglio more than expected).

Fields of papers citing papers by M. Bergaglio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Bergaglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Bergaglio. The network helps show where M. Bergaglio may publish in the future.

Co-authorship network of co-authors of M. Bergaglio

This figure shows the co-authorship network connecting the top 25 collaborators of M. Bergaglio. A scholar is included among the top collaborators of M. Bergaglio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Bergaglio. M. Bergaglio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Palmieri, Giovannella, Carlo Buonerba, Margaret Ottaviano, et al.. (2014). Capecitabine Plus Gemcitabine in Thymic Epithelial Tumors: Final Analysis of a Phase II Trial. Future Oncology. 10(14). 2141–2147. 27 indexed citations
3.
Murialdo, Roberto, G Pastorino, Manlio Mencoboni, et al.. (2011). Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial. Cancer Chemotherapy and Pharmacology. 68(4). 1009–1016. 3 indexed citations
4.
Palmieri, Giovannella, Piera Federico, Mirella Marino, et al.. (2009). Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Annals of Oncology. 21(6). 1168–1172. 46 indexed citations
5.
Mencoboni, Manlio, et al.. (2008). Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer.. PubMed. 27(6C). 4425–9. 3 indexed citations
6.
Mencoboni, Manlio, et al.. (2008). Primary Adrenal Leiomyosarcoma: A Case Report and Literature Review. SHILAP Revista de lepidopterología. 2. 353–6. 19 indexed citations
7.
Mencoboni, Manlio, et al.. (2006). Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients.. PubMed. 26(3B). 2233–5. 11 indexed citations
8.
Bertelli, Gianfilippo, M. Venturini, Lucia Del Mastro, et al.. (2002). Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Annals of Oncology. 13(6). 883–888. 73 indexed citations
9.
Mastro, Lucia Del, Massimo Costantini, Gabriella Morasso, et al.. (2002). Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. European Journal of Cancer. 38(3). 359–366. 38 indexed citations
10.
Venturini, M., Lucia Del Mastro, Ornella Garrone, et al.. (2002). Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Annals of Oncology. 13(4). 546–552. 18 indexed citations
11.
Venturini, M., Andrea Michelotti, Paola Papaldo, et al.. (2001). Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Annals of Oncology. 12(8). 1097–1106. 21 indexed citations
12.
Bertelli, Gianfilippo, Paola Queirolo, Catia Angiolini, et al.. (2001). Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.. PubMed. 20(5C). 3659–61. 2 indexed citations
13.
14.
Mastro, Lucia Del, M. Venturini, Claudio Viscoli, et al.. (2001). Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. Annals of Oncology. 12(4). 505–508. 13 indexed citations
15.
Angiolini, Catia, M. Venturini, Lucia Del Mastro, et al.. (2000). Capecitabine in association with epirubicin and docetaxel as first line chemotherapy in advanced breast cancer A dose-finding study. Breast Cancer Research and Treatment. 64(1). 123. 8 indexed citations
16.
Esposito, Mauro, M. Venturini, Maria O. Vannozzi, et al.. (1999). Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients. Journal of Clinical Oncology. 17(4). 1132–1132. 61 indexed citations
17.
Venturini, M., et al.. (1998). [Use of erythropoietin in oncology].. PubMed. 83(4 Suppl 2). S26–30. 8 indexed citations
18.
Mastro, Lucia Del, M. Venturini, Ornella Garrone, et al.. (1996). 89 O - Effecf of previous adjuvant chemotherapy on the activity and efficacy of cef regimen in metastatic breast cancer patients. European Journal of Cancer. 32. S18–S18. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mustafa Yaylacı Breakdown of academic impact, for papers by M Izuo Breakdown of academic impact, for papers by Izabella Czajka-Oraniec Breakdown of academic impact, for papers by N. Panza Breakdown of academic impact, for papers by Başak Oyan Breakdown of academic impact, for papers by Orren Beaty Breakdown of academic impact, for papers by Anne Pike Breakdown of academic impact, for papers by Qing Huang Breakdown of academic impact, for papers by Maddalena Grosso Breakdown of academic impact, for papers by Virendra Patil
Rankless by CCL
2026